The University of Bristol and spin-out company Imophoron have announced they are ready to test COVID-19 vaccine candidates in a pre-clinical program.
Apr 8, 2020
0
210
Scientists at The Scripps Research Institute (TSRI) have made another important advance in HIV vaccine design. The development was possible thanks to previous studies at TSRI showing the structures of a protein on HIV's surface, ...
May 26, 2017
1
209
A phase 2 trial of an Ad5 vectored COVID-19 vaccine candidate, conducted in China, has found that the vaccine is safe and induces an immune response, according to new research published in The Lancet.
Jul 20, 2020
0
1150
An experimental DNA-based vaccine protected monkeys from infection with the birth defects-causing Zika virus, and it has proceeded to human safety trials, researchers report.
Sep 22, 2016
2
234
University of Alabama at Birmingham researchers report additional preclinical evidence of the potency of a single-dose, intranasal COVID-19 vaccine candidate—AdCOVID—that was created by Altimmune Inc., a Maryland-based ...
May 11, 2021
0
33
A vaccine developed at The Scripps Research Institute (TSRI) to block the "high" of heroin has proven effective in non-human primates. This is the first vaccine against an opioid to pass this stage of preclinical testing.
Jun 6, 2017
1
372
An HIV vaccine candidate developed at the Duke Human Vaccine Institute triggered low levels of an elusive type of broadly neutralizing HIV antibodies among a small group of people enrolled in a 2019 clinical trial.
May 17, 2024
0
63
Human immunodeficiency virus is known to be a highly variable virus that adapts to a person's immune response during the lifetime infection, and a new study published in Nature Medicine shows that viral adaptation in HIV ...
May 16, 2016
0
101
The VLA1553 vaccine candidate for chikungunya disease was generally well tolerated and produced an immune response in 99% (263/266) of participants, according to a phase 3 randomized controlled trial published in The Lancet.
Jun 12, 2023
0
40
Prime Minister Justin Trudeau announced a deal Friday to procure 76 million doses of the first made-in-Canada COVID-19 vaccine candidate, enough for the entire population if it proves effective.
Oct 23, 2020
0
1
